KMO and depressive symptom measurement: While direct clinical evidence in patients of depression that inflammation activates microglia and upregulates KMO within the brain is lacking, it is feasible that inflammation induces an imbalance in kynurenine metabolism elevating neurotoxic QA production that results in depression-related symptoms (10, 156).